Physician profile
John B Murphy
NPI 1972565646
$2,335.98
in general payments reported to CMS, 2019-2025
26 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.91 · 2020: $159 · 2021: $561 · 2022: $539 · 2023: $445 · 2024: $256 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.86 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Welch Allyn | $263.41 | 2021 | |
| Baxter Healthcare | $215.52 | 2022 | |
| Lilly USA, LLC | $136.44 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $128.97 | 2022-2024 | |
| Glaxosmithkline, LLC. | $112.61 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $85.70 | 2019-2023 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $69.84 | 2021-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $60.67 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.69 | 2020-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $40.94 | 2020 | |
| Merck Sharp & Dohme LLC | $36.37 | 2021-2022 | |
| Forte Bio-Pharma LLC | $35.46 | 2023 | Prolate, Nalocet |
| Nestle Healthcare Nutrition INC. | $26.99 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $24.01 | 2023 | Belbuca |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $20.06 | 2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $17.47 | 2023 | Cologuard Collection Kit |
| Grt US Holding, INC. | $17.23 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.60 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.04 | 2023 | Quviviq |
| Genentech USA, INC. | $15.39 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.84 | 2020 | |
| Pfizer INC. | $14.73 | 2023 | |
| Allergan, INC. | $13.86 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.